title: Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.
abstract: In this study, we investigated the efficacy of sequential cytokine-induced killer cell (CIK) immunotherapy with gemcitabine plus cisplatin (GC) regimen chemotherapy in metastatic nasopharyngeal carcinoma (NPC) patients. Between September 2006 and April 2010, 222 NPC patients with distant metastasis after radiotherapy completion were retrospectively analyzed: 112 patients received 4-6 cycles of GC chemotherapy at 4-week intervals, followed by at least 4 cycles of CIK immunotherapy at 2-week intervals (GC+CIK group); the remaining 110 patients received 4-6 cycles of GC chemotherapy alone (GC group). The evaluation of long-term efficacy showed that the progression-free survival (PFS) rate was significantly higher in the GC+CIK group (log-rank test; p = 0.009), as was the overall survival (OS) rate (p = 0.006). In conclusion, sequential CIK treatment may be effective in enhancing the therapeutic efficacy of GC chemotherapy for metastatic NPC patients. This study provides a basis for alternative therapeutic strategies for metastatic NPC.
authors.affiliation: State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China; Department of Endoscopy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
authors.forename: Yin
authors.initials: Y
authors.lastname: Li
authors.affiliation: State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China; Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
authors.forename: Ke
authors.initials: K
authors.lastname: Pan
authors.affiliation: State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China; Department of Imaging and Invention Radiology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
authors.forename: Li-zhi
authors.initials: LZ
authors.lastname: Liu
authors.affiliation: State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China; Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
authors.forename: Yong-qiang
authors.initials: YQ
authors.lastname: Li
authors.affiliation: State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China; Department of Radiation, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
authors.forename: Mo-fa
authors.initials: MF
authors.lastname: Gu
authors.affiliation: Cancer Center, The People's Hospital of Guangdong Province, Guangzhou, 510089, P. R. China.
authors.forename: Hua
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Cancer Institute, The Second Clinical Medical College, Jinan University, Shenzhen People's Hospital, Shenzhen, China, Shenzhen, 518020, P. R. China.
authors.forename: Wei-xi
authors.initials: WX
authors.lastname: Shen
authors.affiliation: State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China; Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
authors.forename: Jian-chuan
authors.initials: JC
authors.lastname: Xia
authors.affiliation: State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China; Department of Endoscopy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
authors.forename: Jian-jun
authors.initials: JJ
authors.lastname: Li
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D024221:Antineoplastic Protocols; D002277:Carcinoma; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D055612:Cytokine-Induced Killer Cells / Q000276:immunology*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D009362:Neoplasm Metastasis; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine